Stockscreener 앱 받기
143.63
1.59%
-2.32
시간 외 거래:
143.85
0.22
+0.15%
전일 마감가:
$145.95
열려 있는:
$145
하루 거래량:
10.44M
Relative Volume:
1.11
시가총액:
$354.36B
수익:
$65.51B
순이익/손실:
$8.93B
주가수익비율:
40.42
EPS:
3.5532
순현금흐름:
$14.12B
1주 성능:
-1.25%
1개월 성능:
-2.21%
6개월 성능:
+20.63%
1년 성능:
+69.39%
1일 변동 폭
$143.53
$147.41
1주일 범위
$142.66
$152.34
52주 변동 폭
$82.01
$156.92
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
143.63 | 354.36B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,240.34 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.79 | 611.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
282.68 | 499.53B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
150.20 | 285.49B | 54.66B | 13.58B | 16.05B | 7.0171 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2026-08-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-08-12 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2026-05-06 | 재개 | Citigroup | Neutral |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-02-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-08 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-10-13 | 재개 | Citigroup | Neutral |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors. - The Motley Fool
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Novo Nordisk and Eli Lilly Just Got Some Fantastic News - The Motley Fool
Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too? - The Motley Fool
Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? - The Motley Fool
Goldman Sachs Adjusts Price Target on Merck & Co to $155 From $160 - marketscreener.com
Milestone Asset Management LLC Sells 9,248 Shares of Merck & Co., Inc. $MRK - MarketBeat
8,527 Shares of Merck & Co., Inc. $MRK Acquired by Neumann Capital Management LLC - MarketBeat
Merck & Co., Inc. $MRK Stock: State of Alaska Department of Revenue Reduces Stake - MarketBeat
18,326 Merck & Co., Inc. $MRK Shares Sold by Ninety One UK Ltd - MarketBeat
1,133,024 Merck & Co., Inc. $MRK Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Curated Wealth Partners LLC Sells 127,541 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA Vaccine - Yahoo Finance
Merck (NYSE: MRK) 2026 notes are slated for voluntary withdrawal from NYSE listing. - Stock Titan
Merck & Co., Inc. (MRK) Options Chain - Yahoo! Finance Canada
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock - Zacks Investment Research
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock - Yahoo Finance
VMS Asset Management Limited Makes New Investment in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Position Lessened by HBW Advisory Services LLC - MarketBeat
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? - Zacks Investment Research
Western Financial Corp CA Acquires 29,043 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Acquired by Strategy Asset Managers LLC - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Godsey & Gibb Inc. - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Stock Jumps 3.6%Still a Buy? - MarketBeat
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? - Zacks Investment Research
History Says This Is Hands-Down the Best ETF to Buy if a Bear Market Is Coming - The Motley Fool
Merck (MRK) Dips More Than Broader Market: What You Should Know - Zacks Investment Research
Merck (MRK) Dips More Than Broader Market: What You Should Know - Yahoo Finance
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Here's What to Expect From Merck & Co.'s Next Earnings Report - Yahoo Finance
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors - Yahoo Finance
Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates - Zacks Investment Research
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock? - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH? - The Motley Fool
Merck's experimental eye drug meets goal in trial, but raises safety concerns (MRK:NYSE) - Seeking Alpha
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell? - The Motley Fool
Merck & Co., Inc. $MRK Stock Holdings Raised by Stokes Capital Advisors LLC - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Castle Rock Wealth Management LLC - MarketBeat
MERCK & CO INC MERCK & CO ORD (0QAH.L) Q2 FY2026 earnings call transcript - Yahoo Finance
11,142 Merck & Co., Inc. $MRK Shares Bought by Wedmont Private Capital - MarketBeat
Merck & Co., Inc. $MRK Position Reduced by Brown Shipley& Co Ltd - MarketBeat
19,456 Merck & Co., Inc. $MRK Shares Sold by Douglas Lane & Associates LLC - MarketBeat
Merck & Co., Inc. $MRK Position Raised by Mn Services Vermogensbeheer B.V. - MarketBeat
Farther Finance Advisors LLC Acquires 11,956 Shares of Merck & Co., Inc. $MRK - MarketBeat
Rep. Maria Elvira Salazar Sells Off Shares of Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Is Merck (NYSE:MRK) Gaining Fresh Momentum After Latest Target Boost? - Kalkine Media
Quintet Private Bank Europe S.A. Grows Stock Position in Merck & Co., Inc. $MRK - MarketBeat
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe - Zacks Investment Research
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
머크앤드컴퍼니 주식 (MRK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| CHIRFI GUINDO | Officer |
Aug 13 '26 |
Proposed Sale |
135.00 |
10,000 |
1,350,000 |
0 |
| JENNIFER L ZACHARY | Officer |
Aug 12 '26 |
Proposed Sale |
133.46 |
80,315 |
10,718,495 |
0 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 12 '26 |
Proposed Sale |
131.63 |
11,699 |
1,539,992 |
0 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 12 '26 |
Sale |
131.63 |
11,699 |
1,539,992 |
110,167 |
| Zachary Jennifer | EVP, General Counsel |
Aug 12 '26 |
Option Exercise |
109.78 |
54,927 |
6,029,637 |
125,824 |
| Zachary Jennifer | EVP, General Counsel |
Aug 12 '26 |
Sale |
133.46 |
80,315 |
10,718,495 |
45,509 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 11 '26 |
Sale |
131.76 |
12,837 |
1,691,426 |
121,866 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 11 '26 |
Proposed Sale |
131.76 |
12,837 |
1,691,426 |
0 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 10 '26 |
Sale |
130.43 |
20,784 |
2,710,951 |
134,703 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 10 '26 |
Proposed Sale |
130.43 |
20,784 |
2,710,951 |
0 |
0.28%
자본화:
|
볼륨(24시간):